MX374605B - Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria. - Google Patents

Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.

Info

Publication number
MX374605B
MX374605B MX2018005446A MX2018005446A MX374605B MX 374605 B MX374605 B MX 374605B MX 2018005446 A MX2018005446 A MX 2018005446A MX 2018005446 A MX2018005446 A MX 2018005446A MX 374605 B MX374605 B MX 374605B
Authority
MX
Mexico
Prior art keywords
treatment
jak kinase
compounds
kinase inhibitor
respiratory disease
Prior art date
Application number
MX2018005446A
Other languages
English (en)
Spanish (es)
Other versions
MX2018005446A (es
Inventor
Anne- Marie Beausoleil
Cameron Smith
Gary E L Brandt
Gene Timothy Fass
John R Jacobsen
Lan Jiang
Orden Lori Jean Van
Marta Dabros
Melissa Fleury
Miroslav Rapta
Noah Benjamin
Paul R Fatheree
Pierre- Jean COLSON
Steven D E Sullivan
Venkat R Thalladi
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2018005446A publication Critical patent/MX2018005446A/es
Publication of MX374605B publication Critical patent/MX374605B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2018005446A 2015-11-03 2016-11-02 Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria. MX374605B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250113P 2015-11-03 2015-11-03
PCT/US2016/059999 WO2017079205A1 (en) 2015-11-03 2016-11-02 Jak kinase inhibitor compounds for treatment of respiratory disease

Publications (2)

Publication Number Publication Date
MX2018005446A MX2018005446A (es) 2018-08-01
MX374605B true MX374605B (es) 2025-03-06

Family

ID=57442794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005446A MX374605B (es) 2015-11-03 2016-11-02 Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.

Country Status (22)

Country Link
US (6) US10100049B2 (enExample)
EP (1) EP3371186A1 (enExample)
JP (1) JP6800969B2 (enExample)
KR (1) KR20180073687A (enExample)
CN (1) CN108349972B (enExample)
AU (1) AU2016350816B2 (enExample)
BR (1) BR112018008966B1 (enExample)
CA (1) CA3001542C (enExample)
CL (1) CL2018001145A1 (enExample)
CO (1) CO2018005640A2 (enExample)
EA (1) EA034914B1 (enExample)
HK (1) HK1252685A1 (enExample)
IL (1) IL258772B (enExample)
MX (1) MX374605B (enExample)
MY (1) MY195427A (enExample)
NZ (1) NZ741737A (enExample)
PH (1) PH12018500828B1 (enExample)
SA (1) SA518391470B1 (enExample)
TW (1) TWI710560B (enExample)
UA (1) UA123633C2 (enExample)
WO (1) WO2017079205A1 (enExample)
ZA (1) ZA201802496B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
DK3371185T3 (da) 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2018165392A1 (en) * 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
WO2018204233A1 (en) * 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR20200003121A (ko) * 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형
WO2019104225A1 (en) 2017-11-22 2019-05-31 Dauntless 2, Inc. Therapeutic compound formulations
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
UA127328C2 (uk) * 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
JP2021535176A (ja) * 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
FI3837258T3 (fi) * 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
US12209092B2 (en) 2018-11-19 2025-01-28 New York University Inhibitors of GLI1 as therapeutic agents
HUE067145T2 (hu) * 2019-02-25 2024-10-28 Henan Medinno Pharmaceutical Tech Co Ltd JAK inhibitor vegyület és alkalmazása
CN114075200A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 用于治疗重症肺炎的jak抑制剂化合物
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
JP7580136B2 (ja) * 2019-12-30 2024-11-11 路良 Jak阻害剤化合物及びその使用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
WO2022204473A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound
EP4359402B1 (en) * 2021-06-25 2026-03-11 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
US20250288561A1 (en) 2022-05-05 2025-09-18 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
JP5161233B2 (ja) 2006-10-19 2013-03-13 ライジェル ファーマシューティカルズ, インコーポレイテッド 自己免疫疾患の処置のためのjakキナーゼの阻害剤としての2,4−ピリミジンアミン誘導体
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CN102131389A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
WO2010039825A2 (en) 2008-10-01 2010-04-08 Array Biopharma Inc. IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN106420756A (zh) 2009-07-28 2017-02-22 里格尔药品股份有限公司 抑制jak途径的组合物和方法
LT3001903T (lt) * 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
TW201513861A (zh) * 2013-01-17 2015-04-16 Galapagos Nv 用於治療退化性及發炎疾病之新穎化合物
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
KR20170002623A (ko) 2014-05-14 2017-01-06 화이자 인코포레이티드 피라졸로피리딘 및 피라졸로피리미딘
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
DK3371185T3 (da) 2015-11-03 2020-11-30 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer
UA123633C2 (uk) 2015-11-03 2021-05-05 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Сполуки інгібітору jak-кінази для лікування респіраторного захворювання
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2018165392A1 (en) 2017-03-09 2018-09-13 Theravance Biopharma R&D Ip, Llc Jak inhibitors containing a 4-membered heterocyclic amide
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형
WO2018204233A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
UA127328C2 (uk) 2018-09-04 2023-07-19 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі 5-7-членні гетероциклічні аміди як інгібітори jak
JP2021535176A (ja) 2018-09-04 2021-12-16 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jak阻害剤およびその中間体を調製するためのプロセス
FI3837258T3 (fi) 2018-09-04 2024-05-27 Theravance Biopharma R&D Ip Llc Dimetyyliaminoatsetidiiniamideja jak-estäjinä
KR20210084512A (ko) 2018-10-29 2021-07-07 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 억제제로서 2-아자비시클로 헥산 화합물
WO2022204473A1 (en) 2021-03-26 2022-09-29 Theravance Biopharma R&D Ip, Llc Crystalline form of a dihydrochloride salt of a jak inhibitor compound

Also Published As

Publication number Publication date
US20210130351A1 (en) 2021-05-06
PH12018500828B1 (en) 2023-06-30
NZ741737A (en) 2023-11-24
US11718616B2 (en) 2023-08-08
JP6800969B2 (ja) 2020-12-16
US20190106420A1 (en) 2019-04-11
US10100049B2 (en) 2018-10-16
US10913740B2 (en) 2021-02-09
US20180319796A1 (en) 2018-11-08
ZA201802496B (en) 2025-01-29
JP2018531982A (ja) 2018-11-01
AU2016350816A1 (en) 2018-05-17
WO2017079205A1 (en) 2017-05-11
CA3001542C (en) 2021-02-16
MY195427A (en) 2023-01-20
US10526330B2 (en) 2020-01-07
AU2016350816B2 (en) 2020-06-25
CN108349972A (zh) 2018-07-31
TWI710560B (zh) 2020-11-21
UA123633C2 (uk) 2021-05-05
BR112018008966B1 (pt) 2023-05-02
SA518391470B1 (ar) 2021-03-31
US20200087303A1 (en) 2020-03-19
IL258772B (en) 2021-01-31
IL258772A (en) 2018-06-28
EA201891091A1 (ru) 2018-12-28
CN108349972B (zh) 2021-06-08
HK1252685A1 (zh) 2019-05-31
EP3371186A1 (en) 2018-09-12
CA3001542A1 (en) 2017-05-11
CL2018001145A1 (es) 2018-07-06
US20170121327A1 (en) 2017-05-04
KR20180073687A (ko) 2018-07-02
US10183942B2 (en) 2019-01-22
EA034914B1 (ru) 2020-04-06
US20220306624A1 (en) 2022-09-29
CO2018005640A2 (es) 2018-05-31
BR112018008966A2 (pt) 2018-11-27
PH12018500828A1 (en) 2018-10-29
TW201726673A (zh) 2017-08-01
US11299492B2 (en) 2022-04-12
MX2018005446A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
MX374605B (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
MX2020011774A (es) Compuestos de naftiridina como inhibidores de quinasa jak.
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
EA201791576A1 (ru) Ингибитор jak
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MX375674B (es) Compuestos de carboxamida inhibidores de la actividad de cinasa rip2.
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX373154B (es) Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12020500528A1 (en) Pyrimidine compound as jak kinase inhibitor
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790632A1 (ru) 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы

Legal Events

Date Code Title Description
FG Grant or registration